Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 5/20 | 0.38 |
| ▸ | F7 | P08709 | 4/20 | 0.38 |
| ▸ | F3 | P13726 | 3/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.38 |
| ▸ | F2 | P00734 | 3/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | STK4 | Q13043 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7139776 | 0.92 | GAA (0.36) | PDE10AGAAKDM4EKMT2ACYP2C9 | |
| SCHEMBL7147081 | 0.89 | MGLL (0.35) | PDE10AGAAKDM4EKMT2ARET | |
| SCHEMBL7147108 | 0.89 | PDE10A (0.35) | PDE10AGAAKDM4EKMT2ACYP2C9 | |
| SCHEMBL7144088 | 0.89 | SCN9A (0.38) | PDE10AGAAKDM4EKMT2ACYP2C9 | |
| SCHEMBL7149114 | 0.88 | F2 (0.42) | PDE10AGAAKMT2AF10F7 | |
| SCHEMBL5883280 | 0.85 | F7 (0.53) | GAAKDM4EKMT2AF10F7 | |
| SCHEMBL5883884 | 0.84 | F10 (0.38) | GAAKDM4EKMT2AF10F7 | |
| SCHEMBL5882529 | 0.83 | F10 (0.38) | GAAKDM4EKMT2AF10F7 | |
| SCHEMBL7141690 | 0.83 | F7 (0.58) | F10F7F3PRSS1F2 | |
| SCHEMBL7139643 | 0.83 | F7 (0.58) | F10F7F3PRSS1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548694-B2 | Anticoagulants | HOFFMAN-LA ROCHE INC. | 2003-04-15 | — | — | US | disclosed |
| EP-1289939-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-12 | — | — | EP | disclosed |
| US-20020004608-A1 | N-(4-carbamimidoyl-phenyl)-glycine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2002-01-10 | — | — | US | disclosed |
| WO-2001090051-A1 | PHENYLGLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004608-A1 | N-(4-carbamimidoyl-phenyl)-glycine derivatives | GLS, SLC6A5, GLRA1 | PDE10A 942/4885GAA 1839/4885KDM4E 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.